Department of Clinical Pharmacy, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, Sichuan, China.
Anticancer Drugs. 2021 Nov 1;32(10):991-1002. doi: 10.1097/CAD.0000000000001110.
The objective of the study was to evaluate and summarize the evidence from systematic reviews and meta-analyses regarding the efficacy and safety of Aidi injection combined with chemotherapy in the treatment of cancer patients. PubMed, EMBASE, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Chong qing VIP databases, and Wanfang databases were searched for systematic reviews/meta-analyses on the topic of Aidi treating cancer patients published from inception to 20 December 2020. Google Scholar and OpenGrey were searched for grey literature and International Prospective Register of Systematic Reviews for ongoing reviews. Two investigators independently selected eligible studies, extracted data, and assessed the methodological quality of included systematic reviews/meta-analyses using the measurement tool to assess systematic reviews 2 (AMSTAR-2) tool, and the strength of evidence was assessed with the grade of recommendation, assessment, development, and evaluation (GRADE) system. Twenty-seven systematic reviews/meta-analyses were identified in the study. The methodological quality of all 27 systematic reviews/meta-analyses were critically low when evaluated by AMSTAR-2, and the evidence quality of all outcomes rated as either low or very low based on the GRADE system. The available evidence is currently insufficient to support or refute the use of Aidi in the treatment of cancer patients, thus high-quality trials with large sample sizes are needed to explore its efficacy and safety in cancer patients.
本研究旨在评估和总结系统评价和荟萃分析关于艾迪注射液联合化疗治疗癌症患者的疗效和安全性的证据。检索了 PubMed、EMBASE、Web of Science、Cochrane 图书馆、中国知网、重庆 VIP 数据库和万方数据库，以获取 2020 年 12 月 20 日之前发表的关于艾迪治疗癌症患者的系统评价/荟萃分析。Google Scholar 和 OpenGrey 用于检索灰色文献，国际前瞻性系统评价注册中心用于检索正在进行的评价。两名研究者独立选择合格的研究，提取数据，并使用评估系统评价的测量工具 2（AMSTAR-2）工具评估纳入的系统评价/荟萃分析的方法学质量，使用推荐、评估、发展和评价（GRADE）系统评估证据质量。研究共确定了 27 项系统评价/荟萃分析。通过 AMSTAR-2 评估，所有 27 项系统评价/荟萃分析的方法学质量均为极低，根据 GRADE 系统，所有结局的证据质量均评为低或极低。目前的证据还不足以支持或反驳艾迪在癌症患者治疗中的应用，因此需要高质量、大样本的试验来探索其在癌症患者中的疗效和安全性。
